WO1994015958A3 - Peptide inhibitors of cell adhesion - Google Patents

Peptide inhibitors of cell adhesion Download PDF

Info

Publication number
WO1994015958A3
WO1994015958A3 PCT/IB1994/000026 IB9400026W WO9415958A3 WO 1994015958 A3 WO1994015958 A3 WO 1994015958A3 IB 9400026 W IB9400026 W IB 9400026W WO 9415958 A3 WO9415958 A3 WO 9415958A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell adhesion
peptide inhibitors
adhesion
disclosed
cyclized
Prior art date
Application number
PCT/IB1994/000026
Other languages
French (fr)
Other versions
WO1994015958A2 (en
Inventor
Shiu-Lang Ng Chiang
Pina M Cardarelli
Thomas J Lobl
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Priority to KR1019950702798A priority Critical patent/KR960700270A/en
Priority to EP94906984A priority patent/EP0677060A1/en
Priority to JP6516421A priority patent/JPH08505628A/en
Publication of WO1994015958A2 publication Critical patent/WO1994015958A2/en
Publication of WO1994015958A3 publication Critical patent/WO1994015958A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cyclized integrin receptor antagonists useful in modulating cell adhesion, including adhesion related to fibronectin, as well as leukocyte adhesion to endothelial cells, are disclosed. Methods for synthesizing, testing, formulating, and using the compounds as therapeutic agents are also disclosed.
PCT/IB1994/000026 1993-01-08 1994-01-07 Peptide inhibitors of cell adhesion WO1994015958A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1019950702798A KR960700270A (en) 1993-01-08 1994-01-07 PEPTIDE INHIBITORS OF CELL ADHESION
EP94906984A EP0677060A1 (en) 1993-01-08 1994-01-07 Peptide inhibitors of cell adhesion
JP6516421A JPH08505628A (en) 1993-01-08 1994-01-07 Peptide type cell adhesion inhibitor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US177393A 1993-01-08 1993-01-08
US08/001,773 1993-01-08
CN94115995A CN1114961A (en) 1993-01-08 1994-07-11 Peptide inhibitors of cell adhesion

Publications (2)

Publication Number Publication Date
WO1994015958A2 WO1994015958A2 (en) 1994-07-21
WO1994015958A3 true WO1994015958A3 (en) 1994-09-29

Family

ID=37075853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1994/000026 WO1994015958A2 (en) 1993-01-08 1994-01-07 Peptide inhibitors of cell adhesion

Country Status (6)

Country Link
EP (1) EP0677060A1 (en)
JP (1) JPH08505628A (en)
CN (1) CN1114961A (en)
CA (1) CA2153228A1 (en)
SG (1) SG52262A1 (en)
WO (1) WO1994015958A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE174036T1 (en) * 1993-03-29 1998-12-15 Du Pont Merck Pharma PROCESS AND INTERMEDIATE COMPOUNDS FOR PRODUCING PLATES GLYCOPROTEIN IIB/IIIA INHIBITORS
US5811391A (en) * 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US7001921B1 (en) 1995-01-23 2006-02-21 Biogen Idec Ma Inc. Cell adhesion inhibitors
US5821329A (en) * 1996-06-06 1998-10-13 Tanabe Seiyaku Co., Ltd. Cyclic peptide inhibitors of β1 and β2 integrin-mediated adhesion
WO1996040781A1 (en) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
WO1997002289A1 (en) * 1995-07-06 1997-01-23 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
US6239108B1 (en) 1996-07-11 2001-05-29 Biogen, Inc. Cell adhesion inhibitors
US6686350B1 (en) 1996-07-25 2004-02-03 Biogen, Inc. Cell adhesion inhibitors
DK0914605T3 (en) 1996-07-25 2007-09-10 Biogen Idec Inc Molecule model for VLA-4 inhibitors
DE19647381A1 (en) 1996-11-15 1998-05-20 Hoechst Ag New heterocycles as leukocyte adhesion inhibitors and VLA-4 antagonists
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
JP2002506423A (en) * 1997-04-11 2002-02-26 イーライ・リリー・アンド・カンパニー Combinatorial library of peptidomimetic macrocycles and methods therefor
DE19741235A1 (en) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them
DE19741873A1 (en) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh New 5-ring heterocycles, their preparation, their use and pharmaceutical preparations containing them
US6511961B1 (en) 1997-11-13 2003-01-28 Toray Industries, Inc. Cyclic peptides and medicinal use thereof
DE19751251A1 (en) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituted imidazolidine derivatives, their manufacture, their use and pharmaceutical preparations containing them
DE19821483A1 (en) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh New imidazolidine derivatives useful as leukocyte adhesion and migration inhibitors and/or VLA-4 receptor antagonists for treating E.G. inflammatory and allergic disorders
PL198189B1 (en) 1998-05-28 2008-06-30 Biogen Idec Ma A novel vla-4 inhibitor: omepupa-v
WO1999065944A1 (en) * 1998-06-15 1999-12-23 Ixsys Incorporated PEPTIDE INHIBITORS OF αVβ3 AND αVβ¿5?
TR200100734T2 (en) 1998-09-14 2001-07-23 Board Of Regents, The University Of Texas System Improving bone resorption induced by multiple myeloma and myeloma using integrin antagonists
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
DE19922462A1 (en) 1999-05-17 2000-11-23 Aventis Pharma Gmbh New phenylureidobenzyl-substituted spiro-imidazolidinedione derivatives, are inhibitors of leukocyte adhesion or migration or VLA-4 receptors, useful e.g. for treating inflammatory or allergic disease
JP2003506491A (en) 1999-08-13 2003-02-18 バイオジェン インコーポレイテッド Cell adhesion inhibitor
EP1242118B1 (en) 1999-12-16 2009-11-11 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
US6875743B1 (en) 2000-11-28 2005-04-05 Biogen, Inc. Cell adhesion inhibitors
DE10111877A1 (en) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them
DE10137595A1 (en) 2001-08-01 2003-02-13 Aventis Pharma Gmbh New 3-alkylaminoalkyl-imdazolidin-4-one derivatives, are VLA-4 receptor and leukocyte adhesion and/or migration inhibitors, useful e.g. for treating inflammatory, allergic, autoimmune or cardiovascular disease
AU2003211560A1 (en) 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
US7570871B2 (en) 2002-11-12 2009-08-04 Koninklijke Philips Electronics N.V. Continue recording channel feature for personal video recorder
AU2004274051A1 (en) 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
RU2390520C2 (en) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Novel phenylalanine derivatives
CA2549851C (en) 2004-01-21 2012-09-11 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US20130116184A1 (en) 2010-04-02 2013-05-09 The Regents Of The University Of Michigan RFamide-Related Peptides and Methods Thereof
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
CN110423265A (en) * 2019-04-03 2019-11-08 中国药科大学 A kind of preparation method and purposes of cyclic peptide TRF2 inhibitor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008739A1 (en) * 1990-11-13 1992-05-29 The Scripps Research Institute Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation
WO1992008476A1 (en) * 1990-11-07 1992-05-29 The Scripps Research Institute Peptides that inhibit platelet binding of adhesion molecules
EP0537654A2 (en) * 1991-10-18 1993-04-21 F. Hoffmann-La Roche Ag Anti-alpha6-integrin-antibodies
US5225531A (en) * 1992-04-09 1993-07-06 Washington University Hexapeptide Lys Gly Ala Gly Asp Val
WO1993020229A1 (en) * 1992-04-03 1993-10-14 Genentech, Inc. ANTIBODIES TO ALPHAvBETA3 INTEGRIN

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008476A1 (en) * 1990-11-07 1992-05-29 The Scripps Research Institute Peptides that inhibit platelet binding of adhesion molecules
WO1992008739A1 (en) * 1990-11-13 1992-05-29 The Scripps Research Institute Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation
EP0537654A2 (en) * 1991-10-18 1993-04-21 F. Hoffmann-La Roche Ag Anti-alpha6-integrin-antibodies
WO1993020229A1 (en) * 1992-04-03 1993-10-14 Genentech, Inc. ANTIBODIES TO ALPHAvBETA3 INTEGRIN
US5225531A (en) * 1992-04-09 1993-07-06 Washington University Hexapeptide Lys Gly Ala Gly Asp Val

Also Published As

Publication number Publication date
SG52262A1 (en) 1998-09-28
CA2153228A1 (en) 1994-07-21
WO1994015958A2 (en) 1994-07-21
JPH08505628A (en) 1996-06-18
CN1114961A (en) 1996-01-17
EP0677060A1 (en) 1995-10-18

Similar Documents

Publication Publication Date Title
WO1994015958A3 (en) Peptide inhibitors of cell adhesion
CA2314607A1 (en) Use of ppar-.gamma. activators in dermatology
TR200101398T2 (en) Pyrrolidine derivatives-CCR-3 receptor antagonists.
MX9706069A (en) Novel dipeptide amidines as thrombin inhibitors.
WO1992007830A3 (en) Oxindole peptide antagonists
CA2078572A1 (en) Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
EP2016953A3 (en) Vascular endothelial cell growth factor antagonists and uses thereof
MX9806064A (en) Enzyme composition for tissue dissociation.
IE45086L (en) Amino acids.
WO2001038547A3 (en) Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
WO2001068586A3 (en) α4β1 AND α4β7 INTEGRIN INHIBITORS
EP1746160A3 (en) Hepatocyte growth factor receptor antagonists and uses thereof
ATE214607T1 (en) USE OF ALDOSTERONE ANTAGONISTS TO INHIBIT MYOCARDIAL FIBROSIS
MXPA01007765A (en) Methods for inhibiting brain tumor growth.
AU5147598A (en) Methods for reversibly inhibiting myelopoiesis in mammalian tissue
IL142905A0 (en) Functional antagonists of hedgehog activity
CA2298018A1 (en) Methods and compositions for inhibiting angiogenesis
DK1007537T3 (en) Receptor protein designated 2F1
PL327200A1 (en) Endothelium cells proliferation inhibitor and methods of using same
NO971341D0 (en) Promoter for receptor tyrosine kinase TIE
HUP9902017A3 (en) Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants
WO1997031936A3 (en) Novel ortho-naphthoquinone derivatives, novel synthesis therefor, and their use in the inhibition of neoplastic cell growth
PT883405E (en) AMIDINE-PROTEASE INHIBITORS
MX9801890A (en) Novel human nk3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them.
WO2000044407A8 (en) Materials and methods to inhibit hodgkin and reed sternberg cell growth

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2153228

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994906984

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994906984

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994906984

Country of ref document: EP